BE2019C547I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2019C547I2 BE2019C547I2 BE2019C547C BE2019C547C BE2019C547I2 BE 2019C547 I2 BE2019C547 I2 BE 2019C547I2 BE 2019C547 C BE2019C547 C BE 2019C547C BE 2019C547 C BE2019C547 C BE 2019C547C BE 2019C547 I2 BE2019C547 I2 BE 2019C547I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002010413 | 2002-01-18 | ||
JP2002010447 | 2002-01-18 | ||
PCT/JP2003/000270 WO2003062233A1 (fr) | 2002-01-18 | 2003-01-15 | Derive de 2-acylaminothiazole et son sel |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2019C547I2 true BE2019C547I2 (nl) | 2022-05-17 |
Family
ID=27615666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2019C547C BE2019C547I2 (nl) | 2002-01-18 | 2019-11-06 |
Country Status (17)
Country | Link |
---|---|
US (4) | US7638536B2 (nl) |
EP (2) | EP2314586B1 (nl) |
JP (2) | JP4120586B2 (nl) |
KR (1) | KR101010905B1 (nl) |
CN (1) | CN1319967C (nl) |
BE (1) | BE2019C547I2 (nl) |
CA (1) | CA2472711C (nl) |
CY (2) | CY1114169T1 (nl) |
DK (1) | DK1466912T3 (nl) |
ES (2) | ES2610611T3 (nl) |
FR (1) | FR19C1072I2 (nl) |
HU (1) | HUS1900052I1 (nl) |
LU (1) | LUC00137I2 (nl) |
NL (1) | NL301020I2 (nl) |
PT (1) | PT1466912E (nl) |
SI (1) | SI1466912T1 (nl) |
WO (1) | WO2003062233A1 (nl) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
WO2003062233A1 (fr) | 2002-01-18 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-acylaminothiazole et son sel |
EP1485370B1 (en) * | 2002-03-13 | 2009-03-04 | Janssen Pharmaceutica N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
WO2005007651A1 (ja) * | 2003-07-17 | 2005-01-27 | Astellas Pharma Inc. | 2-アシルアミノチアゾール誘導体又はその塩 |
WO2005014561A1 (ja) * | 2003-08-12 | 2005-02-17 | Shionogi & Co., Ltd. | トロンボポエチン受容体アゴニスト作用を有する化合物 |
US7718808B2 (en) * | 2003-12-26 | 2010-05-18 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
BRPI0418939A (pt) * | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
ATE494895T1 (de) * | 2004-09-20 | 2011-01-15 | Xenon Pharmaceuticals Inc | Pyridin-derivate zur hemmung der menschlichen stearoyl-coa-desaturase |
BRPI0516883A (pt) * | 2004-10-25 | 2008-09-23 | Ligand Pharm Inc | compostos e métodos para modulação da atividade de trombopoietina |
US8552031B2 (en) | 2004-12-08 | 2013-10-08 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
US8134013B2 (en) * | 2004-12-14 | 2012-03-13 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
EP1894930A4 (en) * | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
WO2007004038A1 (en) * | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
WO2007036769A1 (en) * | 2005-07-05 | 2007-04-05 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
EP1904474A4 (en) * | 2005-07-13 | 2010-06-16 | Astrazeneca Ab | NEW PYRIDINE ANALOG |
CA2609319C (en) * | 2005-07-15 | 2014-02-04 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
EP1904488B1 (en) * | 2005-07-20 | 2013-03-06 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and thrombopoietin receptor activators |
KR101350099B1 (ko) | 2005-11-07 | 2014-01-09 | 닛산 가가쿠 고교 가부시키 가이샤 | 하이드라지드 화합물 및 트롬보포이에틴 리셉터 활성화제 |
US20070203153A1 (en) * | 2005-11-08 | 2007-08-30 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
US8093251B2 (en) * | 2006-06-07 | 2012-01-10 | Nissan Chemical Industries, Ltd. | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators |
EP2056826B1 (en) * | 2006-08-08 | 2014-01-08 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
JP5164510B2 (ja) * | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
PT2184279E (pt) | 2007-07-31 | 2015-02-05 | Shionogi & Co | Composição farmacêutica contendo um composto oticamente ativo com atividade de agonista do recetor da trombopoietina e seu intermediário |
ES2331220B1 (es) * | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
CN101888841B (zh) * | 2007-10-09 | 2012-09-26 | 宾夕法尼亚大学理事会 | 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞 |
CN101959515B (zh) * | 2008-02-25 | 2013-06-12 | 默克专利有限公司 | 葡糖激酶激活剂 |
US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
WO2011019990A1 (en) | 2009-08-14 | 2011-02-17 | Eisai, Inc. | Use of e5501 for stimulating platelet production |
GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JP2014144916A (ja) | 2011-08-03 | 2014-08-14 | Astellas Pharma Inc | 2−アシルアミノチアゾール化合物の結晶 |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
AU2012337781B2 (en) | 2011-11-15 | 2017-07-06 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
US9499533B2 (en) | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
TWI647227B (zh) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-醯胺噻唑衍生物或其鹽 |
BR112015022202A2 (pt) | 2013-03-14 | 2017-07-18 | Dart Neuroscience Cayman Ltd | compostos substituídos de naftiridina e quinolina como inibidores da mao |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
AR096788A1 (es) | 2013-07-02 | 2016-02-03 | Bristol Myers Squibb Co | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock |
KR102482844B1 (ko) | 2014-06-06 | 2022-12-30 | 가부시키가이샤 아사히야쿠교 | 2-아실아미노티아졸 유도체 또는 그의 염 |
US9844549B2 (en) | 2014-08-26 | 2017-12-19 | Astellas Pharma Inc. | 2-aminothiazole derivative or salt thereof |
EP3214209B1 (en) | 2014-10-31 | 2020-01-29 | Nissan Chemical Corporation | Ligand-binding fiber and cell culture substrate using said fiber |
JP2019529342A (ja) * | 2016-09-08 | 2019-10-17 | 四川科倫博泰生物医薬股▲フン▼有限公司Sichuan Kelun−Biotech Biopharmaceutical Co., Ltd. | 新型2−アミドチアゾール誘導体、及びその製造方法と用途 |
CN106749226B (zh) * | 2017-03-15 | 2019-12-20 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
CN110586047B (zh) * | 2019-10-08 | 2022-03-11 | 辽宁工业大学 | 一种用于吸附铅离子的改性双醛淀粉制备方法 |
CN111620863A (zh) * | 2020-06-23 | 2020-09-04 | 苏州明锐医药科技有限公司 | 阿曲波帕的制备方法 |
CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
TW205041B (nl) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
JPH078863B2 (ja) | 1989-09-21 | 1995-02-01 | 久光製薬株式会社 | 新規なジフェニルチアゾール誘導体 |
IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
JPH03199451A (ja) | 1989-12-26 | 1991-08-30 | Asahi Chem Ind Co Ltd | エアージェットルーム用筬 |
FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
JP3173876B2 (ja) | 1992-06-26 | 2001-06-04 | 日本パイオニクス株式会社 | 有害ガスの検知システム |
AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
AU685225B2 (en) | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
DE69629341T2 (de) * | 1995-03-09 | 2004-06-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazolderivate |
CA2218479C (en) | 1995-04-28 | 2008-01-15 | Banyu Pharmaceutical Co., Ltd. | 1,4-di-substituted piperidine derivatives |
BR9608587A (pt) * | 1995-06-07 | 1999-01-05 | Glaxo Group Ltd | Composto que se liga ao receptor de trombopoietina composição farmacêutica e processo para o tratamento de um paciente sofrendo de um distúrbio |
US5963666A (en) * | 1995-08-18 | 1999-10-05 | International Business Machines Corporation | Confusion matrix mediated word prediction |
ES2195016T3 (es) * | 1995-10-17 | 2003-12-01 | Daiichi Suntory Pharma Co Ltd | Medicamento contra la trombocitopenia. |
ATE247959T1 (de) | 1996-05-22 | 2003-09-15 | Smithkline Beecham Corp | Nicht peptidische g-csf mimetika |
WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
JPH10212289A (ja) | 1997-01-31 | 1998-08-11 | Kyowa Hakko Kogyo Co Ltd | ピロロフェナンスリジン誘導体 |
WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
JPH11152276A (ja) | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
JP2000044562A (ja) | 1998-07-31 | 2000-02-15 | Kyowa Hakko Kogyo Co Ltd | ピロロフタルイミド誘導体 |
EP1114039A1 (en) | 1998-09-18 | 2001-07-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
WO2000028987A1 (en) * | 1998-11-17 | 2000-05-25 | Smithkline Beecham Corporation | Methods of treating thrombocytopenia |
GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
WO2001007423A1 (fr) * | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1847263A3 (en) | 2000-12-18 | 2009-08-26 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
US20040077697A1 (en) * | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
WO2002062792A1 (fr) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Inhibiteur de jnk |
WO2003062233A1 (fr) | 2002-01-18 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-acylaminothiazole et son sel |
DK1482931T3 (da) | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
EP1513534A2 (en) | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
JP4635130B2 (ja) | 2002-06-11 | 2011-02-16 | 株式会社医薬分子設計研究所 | 神経変性疾患治療剤 |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
WO2004029049A1 (ja) | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
CN1747936A (zh) | 2003-02-12 | 2006-03-15 | 特兰斯泰克制药公司 | 作为治疗试剂的取代吡咯衍生物 |
AU2004225965A1 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
WO2005007651A1 (ja) | 2003-07-17 | 2005-01-27 | Astellas Pharma Inc. | 2-アシルアミノチアゾール誘導体又はその塩 |
WO2005014561A1 (ja) | 2003-08-12 | 2005-02-17 | Shionogi & Co., Ltd. | トロンボポエチン受容体アゴニスト作用を有する化合物 |
US20070203153A1 (en) * | 2005-11-08 | 2007-08-30 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
EP2056826B1 (en) * | 2006-08-08 | 2014-01-08 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
-
2003
- 2003-01-15 WO PCT/JP2003/000270 patent/WO2003062233A1/ja active Application Filing
- 2003-01-15 EP EP11154632.1A patent/EP2314586B1/en not_active Expired - Lifetime
- 2003-01-15 SI SI200332274T patent/SI1466912T1/sl unknown
- 2003-01-15 US US10/500,964 patent/US7638536B2/en active Active
- 2003-01-15 DK DK03700571.7T patent/DK1466912T3/da active
- 2003-01-15 PT PT37005717T patent/PT1466912E/pt unknown
- 2003-01-15 CN CNB038044579A patent/CN1319967C/zh not_active Expired - Lifetime
- 2003-01-15 CA CA2472711A patent/CA2472711C/en not_active Expired - Lifetime
- 2003-01-15 JP JP2003562111A patent/JP4120586B2/ja not_active Expired - Lifetime
- 2003-01-15 ES ES11154632.1T patent/ES2610611T3/es not_active Expired - Lifetime
- 2003-01-15 KR KR1020047010846A patent/KR101010905B1/ko active IP Right Grant
- 2003-01-15 ES ES03700571T patent/ES2416304T3/es not_active Expired - Lifetime
- 2003-01-15 EP EP03700571.7A patent/EP1466912B1/en not_active Expired - Lifetime
-
2008
- 2008-02-04 JP JP2008023950A patent/JP4844574B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-10 US US12/615,968 patent/US8338429B2/en not_active Expired - Lifetime
- 2009-11-10 US US12/615,979 patent/US20100222329A1/en not_active Abandoned
-
2012
- 2012-11-15 US US13/677,520 patent/US8765764B2/en not_active Expired - Lifetime
-
2013
- 2013-07-24 CY CY20131100629T patent/CY1114169T1/el unknown
-
2019
- 2019-11-06 BE BE2019C547C patent/BE2019C547I2/fr unknown
- 2019-11-12 LU LU00137C patent/LUC00137I2/fr unknown
- 2019-12-06 FR FR19C1072C patent/FR19C1072I2/fr active Active
- 2019-12-11 NL NL301020C patent/NL301020I2/nl unknown
- 2019-12-11 HU HUS1900052C patent/HUS1900052I1/hu unknown
- 2019-12-17 CY CY2019045C patent/CY2019045I1/el unknown